Moneycontrol PRO
you are here: HomeNewsLupin
lupin
Jump to
  • Hold Lupin; target of Rs 600: Prabhudas Lilladher Aug 07, 2022 01:29 PM IST

    Hold Lupin; target of Rs 600: Prabhudas Lilladher

    Prabhudas Lilladher recommended hold rating on Lupin with a target price of Rs 600 in its research report dated August 05, 2022.

  • Buy Lupin; target of Rs 780: Sharekhan Aug 06, 2022 10:39 PM IST

    Buy Lupin; target of Rs 780: Sharekhan

    Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 780 in its research report dated August 04, 2022.

  • Neutral Lupin; target of Rs 610: Motilal Oswal Aug 06, 2022 10:00 PM IST

    Neutral Lupin; target of Rs 610: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 610 in its research report dated August 04, 2022.

  • Lupin posts net loss of Rs 89 crore in Q1 Aug 04, 2022 09:52 PM IST

    Lupin posts net loss of Rs 89 crore in Q1

    Total revenue from operations stood at Rs 3,744 crore in the June quarter as against Rs 4,270 crore in the year-ago period, Lupin said in a statement.

  • Lupin Consolidated June 2022 Net Sales at Rs 3,743.84 crore, down 12.33% Y-o-Y Aug 04, 2022 11:33 AM IST

    Lupin Consolidated June 2022 Net Sales at Rs 3,743.84 crore, down 12.33% Y-o-Y

  • Lupin Standalone June 2022 Net Sales at Rs 2,732.49 crore, down 17.55% Y-o-Y Aug 04, 2022 11:22 AM IST

    Lupin Standalone June 2022 Net Sales at Rs 2,732.49 crore, down 17.55% Y-o-Y

  • Lupin swings to loss as US and India business decline, but expects bounceback Aug 04, 2022 06:26 AM IST

    Lupin swings to loss as US and India business decline, but expects bounceback

    "Our numbers are muted in the quarter but we expect a strong bounceback from September quarter," Nilesh Gupta, managing director, Lupin, said.

  • Lupin gets USFDA nod for generic blood pressure lowering drug Jul 25, 2022 08:29 PM IST

    Lupin gets USFDA nod for generic blood pressure lowering drug

  • Lupin Q1 PAT may dip 73.3% YoY to Rs 144.7 cr: ICICI Direct Jul 13, 2022 07:33 PM IST

    Lupin Q1 PAT may dip 73.3% YoY to Rs 144.7 cr: ICICI Direct

    Net Sales are expected to decrease by 6.2 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs 4,007.1 crore, according to ICICI Direct.

  • Lupin Q1 PAT may dip 79.8% YoY to Rs 109.5 cr: Prabhudas Lilladher Jul 08, 2022 05:36 PM IST

    Lupin Q1 PAT may dip 79.8% YoY to Rs 109.5 cr: Prabhudas Lilladher

    Net Sales are expected to decrease by 0.7 percent Y-o-Y (up 9.2 percent Q-o-Q) to Rs 4,240.2 crore, according to Prabhudas Lilladher.

  • Lupin's Somerset manufacturing plant receives EIR from US FDA Jul 07, 2022 11:32 AM IST

    Lupin's Somerset manufacturing plant receives EIR from US FDA

    The US Food and Drug Administration (US FDA) had inspected the facility in March 2022, the company said in a regulatory filing.

  • Lupin gets USFDA nod for generic drug Jun 08, 2022 02:30 PM IST

    Lupin gets USFDA nod for generic drug

    The company has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Ivacaftor tablets, 150 mg strength, Lupin said in a statement.

  • Hold Lupin; target of Rs 610: ICICI Direct May 21, 2022 08:49 PM IST

    Hold Lupin; target of Rs 610: ICICI Direct

    ICICI Direct recommended hold rating on Lupin with a target price of Rs 610 in its research report dated May 20, 2022.

  • Buy Lupin: target of Rs 780: Sharekhan May 21, 2022 08:30 PM IST

    Buy Lupin: target of Rs 780: Sharekhan

    Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 780 in its research report dated May 19, 2022.

  • Neutral Lupin; target of Rs 590: Motilal Oswal May 21, 2022 08:02 PM IST

    Neutral Lupin; target of Rs 590: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 590 in its research report dated May 19, 2022.

  • Lupin: Pricing erosion intensifies in US May 20, 2022 12:18 PM IST

    Lupin: Pricing erosion intensifies in US

    Near-term growth visibility is low due to a lack of major product launches, aggravating pricing erosion and input cost pressure for Lupin

  • Lupin Consolidated March 2022 Net Sales at Rs 3,883.03 crore, up 2.64% Y-o-Y May 19, 2022 11:00 AM IST

    Lupin Consolidated March 2022 Net Sales at Rs 3,883.03 crore, up 2.64% Y-o-Y

  • Lupin Standalone March 2022 Net Sales at Rs 2,855.39 crore, up 13.49% Y-o-Y May 19, 2022 11:00 AM IST

    Lupin Standalone March 2022 Net Sales at Rs 2,855.39 crore, up 13.49% Y-o-Y

  • Lupin partners Yabao to market paediatric products in China Apr 27, 2022 11:41 AM IST

    Lupin partners Yabao to market paediatric products in China

    "It paves the way for us to bring quality paediatric formulations to the growing needs of patients in China," Fabrice Egros, president - corporate development and growth markets, Lupin, said.

  • Lupin gets USFDA nod to market generic drug Apr 18, 2022 03:15 PM IST

    Lupin gets USFDA nod to market generic drug

    The company has received tentative approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application for Tenofovir Alafenamide tablets (25 mg), Lupin said in a statement.

  • Lupin Q4 PAT may dip 49.9% YoY to Rs 230.5 cr: Prabhudas Lilladher Apr 14, 2022 04:52 PM IST

    Lupin Q4 PAT may dip 49.9% YoY to Rs 230.5 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 6.3 percent Y-o-Y (down 3.3 percent Q-o-Q) to Rs 4,021.7 crore, according to Prabhudas Lilladher.

  • Lupin completes acquisition of portfolio of brands from Anglo-French Drugs & Industries Apr 07, 2022 02:04 PM IST

    Lupin completes acquisition of portfolio of brands from Anglo-French Drugs & Industries

    The acquisition will strengthen the company’s India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products, the Mumbai-based drug maker said in a statement.

  • Lupin inks licensing pact with Alvion to market drugs in Southeast Asia Apr 05, 2022 06:52 PM IST

    Lupin inks licensing pact with Alvion to market drugs in Southeast Asia

    The Mumbai-based company said it is committed to providing affordable treatment options to healthcare providers and patients.

  • Lupin gets USFDA nod for generic product Mar 24, 2022 02:14 PM IST

    Lupin gets USFDA nod for generic product

    The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL, Lupin said in a statement.

  • Lupin gets USFDA nod to market generic drug Mar 11, 2022 09:19 PM IST

    Lupin gets USFDA nod to market generic drug

    The Mumbai-based drug firm's product is the generic equivalent of Lundbeck Pharmaceuticals' Sabril for Oral Solution.

Sections
ISO 27001 - BSI Assurance Mark